	Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study. Eur Radiol Englman C, Adebusoye B, Cosenza M, Del Prete A, Dickinson L, Imperiale G, Leni R, Gandaglia G, De Cobelli F, Mallett S, Kirkham A, Moore CM, Giganti F, Brembilla G. PMID: 41652236 [PubMed - as supplied by publisher]
	Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study. Br J Cancer Blanchet B, Puszkiel A, Jouinot A, Bennamoun M, Maillet D, Borchiellini D, Laguerre B, Pannier D, Gross-Goupil M, Chevreau C, Barthélémy P, Tournigand C, Coquan E, Gravis G, Lepicard E, Fridman WH, Sautes-Fridman C, Oudard S, Sun CM, Vano YA. PMID: 41652222 [PubMed - as supplied by publisher]
	Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy Xue A, Wang L, Akerman M, Gogineni A, Coelho A, Potters L, Parashar B. PMID: 41651735 [PubMed - as supplied by publisher]
	Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis. Urology Siguencia F, Heard J, Smith SM, Pagano I, Furuya H, Wu X, Ahdoot M, Rosser CJ. PMID: 41651230 [PubMed - as supplied by publisher]
	Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program. Am J Hum Genet Cheng S, Suger AH, Goss LB, Zhang J, Fuller H, Guo B, Lindström S, Darst BF. PMID: 41650938 [PubMed - indexed for MEDLINE]
	Construction and validation of a competing risk model for specific survival of patients with second primary malignancies after prostate cancer. Medicine (Baltimore) Bao EH, Yang Y, Wang JH, Li Y, Liu Y, Yang L, Hao P. PMID: 41650062 [PubMed - indexed for MEDLINE]
	Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study. Medicine (Baltimore) Jiang M, Sun C, Wang B, Huang Q, Hu Q, Che X. PMID: 41650055 [PubMed - indexed for MEDLINE]
	Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clin Cancer Res Munzur AD, Herberts C, Kwan EM, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Lee ST, Scott AM, Martin AJ, Stockler MR, Zhang AY, Williams SG, Bernales CQ, Donnellan G, Koudjanian M, Parekh K, Bacon JVW, Karsan A, Azad AA, Davis ID, Hofman MS, Wyatt AW. PMID: 41649873 [PubMed - as supplied by publisher]
	Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer. Ann Surg Oncol Mehmud I, Zhang Y, Wu S, Zhang S. PMID: 41649780 [PubMed - as supplied by publisher]
	[Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?]. Urologie Bolenz C, Zengerling F, Kübler H, Hahn O. PMID: 41649558 [PubMed - as supplied by publisher]
	[Current diagnostics and treatment of penile cancer]. Urologie Dräger DL, Protzel C. PMID: 41649557 [PubMed - as supplied by publisher]
	The use of computed tomography during follow-up after ablation of cT1 renal cell carcinoma: evidence for overuse. Eur Radiol Reijerink MAA, van den Brink L, Henderickx MMEL, van Delden OM, Beerlage HP, Bex A, Jamaludin FS, Shahraki MN, Zondervan PJ, Stoker J. PMID: 41649536 [PubMed - as supplied by publisher]
	A Novel Method to Generate Analyte-Specific Specimens for Multi-Omic Studies of Primary Bladder Cancer. Biopreserv Biobank Mojica W, Izydorczak A, Wood T, Hsu J, Wu Y. PMID: 41649158 [PubMed - as supplied by publisher]
	Roles of E3 ubiquitin ligases and deubiquitinating enzymes in renal cell carcinoma. Front Oncol Jiang M, Si W, Huang S, Qu S, Zhang M, Quan Y. PMID: 41647837 [PubMed]
	Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort. ESMO Real World Data Digit Oncol George G, Rowley M, Coolen ACC, Santa Olalla A, Hammar N, Feychting M, Karagiannis SN, Enting D, Van Hemelrijck M. PMID: 41647707 [PubMed]
	Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study. ESMO Real World Data Digit Oncol Tran B, Yeh N, Gayle A, Holmes E, Hu J, Damineni S, Kebede N, Shore N. PMID: 41647700 [PubMed]
	Cost-effectiveness analysis of a biopsy-free diagnostic strategy for prostate cancer using mpMRI and PSMA-PET/CT. BJUI Compass Tung JYM, Lau RS, Teo EPS, Chow KM, Ong JHW, Lu TS, Chen W, Li J, Yang X, Lee AY, Tan YG, Tay KJ, Thang SP, Lam WWC, Law YM, Ho HSS, Cheng CWS, Yuen JS, Chen K. PMID: 41647483 [PubMed]
	Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing. Front Immunol Ning W, Chang P, Zheng J, Chen W. PMID: 41646982 [PubMed - indexed for MEDLINE]
	Identification and diagnostic evaluation of an aptamer targeting prostate-cancer-derived small extracellular vesicles. Mol Ther Nucleic Acids Ding T, Li Y, Xue L, Xiong C, Yu L, He Q, Liu J, Hao X, Zhao D. PMID: 41646885 [PubMed]
	Effect of implementing population-based prostate-specific antigen screening on testing rates and prostate cancer overdiagnosis in England: a statistical modelling study. medRxiv Vickers AJ, Brentnall A. PMID: 41646809 [PubMed]

Articles 1 - 20 / 175806

Page 1 of 8791



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy